UNSPSC 51143407: Ergotamine/hyoscyamine/phenobarbital

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN105. This VA Drug Class (CN105) classifies this compound as belonging to the group ANTIMIGRAINE AGENTS.

UNSPSC 51143407 Ergotamine/hyoscyamine/phenobarbital is a Commodity code that in practice covers a narrow range of pharmaceutical products and related systems. Recent state and local procurement activity under this code diverges significantly from the nominal scope: opportunities are tracking naloxone procurement, therapeutic pharmacy benefit initiatives, and multi-source generic pharmaceutical supply contracts, not the specific branded or combination drugs the code name implies. State and local buyers include county health systems, state health and human services commissions, and multistate cooperative purchasing alliances. Seminole County, Florida, and the Texas Health and Human Services Commission are among the issuing bodies posting opportunities tagged to this code in the past several months, though the mismatch between code taxonomy and actual procurement scope suggests the code may be applied inconsistently or as a catch-all within some jurisdictions' procurement systems.

Geographic activity centers on Florida and Texas, with additional multistate reach through the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), which spans Minnesota, Oregon, and other participating jurisdictions. Representative recent opportunities include Seminole County's IFB60459723LAS, issued June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2026; the Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs; and MMCAP's S1070000015802 RFP, posted January 20, 2026, establishing multi-award contracts for generic pharmaceuticals and OTC products distributed through authorized wholesalers, with proposals due March 26, 2026. The divergence between code name and actual procurement (pharmaceutical supply networks and naloxone systems versus branded combination medications) suggests limited activity truly aligned with the code's nominal scope.